

## Special Issue

# Identification of the Targets to Overcome Clinical Problems in Bladder Cancer

### Message from the Guest Editor

Bladder cancer has been reported to be the 10th most common cancer worldwide. In 2022, it is estimated that it will cause 17,100 deaths in the USA. Nevertheless, effective diagnostic and prognostic markers of bladder cancer have yet to be identified. Recent evidence has suggested that the signaling of steroid hormonal receptors, including the androgen, estrogen and glucocorticoid receptors, was strongly linked with carcinogenesis and progression in bladder cancer. More recently, it has been shown that there are three molecular subtypes in muscle invasive bladder cancer according to their gene expressions (basal, luminal and p53-like luminal). Considering clinical challenges such as a lack of effective markers and potent second-line treatments in bladder cancer, a key target in the diagnosis and prognosis of bladder cancer needs to be identified. Therefore, we believe that by exploring potential targets and summarizing and evaluating recent evidence in this Special Issue, we will contribute to prognostic improvement in bladder cancer patients.

### Guest Editor

Dr. Hiroki Ide

Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan

### Deadline for manuscript submissions

closed (15 May 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/124247](https://mdpi.com/si/124247)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)